A Phase 1 Dose Escalation Study of Protein Arginine Methyltransferase 5 (PRMT5) Inhibitor PRT543 in Patients with Myeloid Malignancies

被引：13

作者：

Patel, Manish R. ^{[1
]}

Monga, Varun ^{[2
]}

Jauhari, Shekeab ^{[1
]}

Stevens, Don ^{[3
]}

Masarova, Lucia ^{[4
]}

McKean, Meredith ^{[5
]}

Mauro, David ^{[6
]}

Viscusi, John ^{[6
]}

Scherle, Peggy ^{[6
]}

Bhagwat, Neha ^{[6
]}

Moore, Andrew ^{[6
]}

Sun, William ^{[6
]}

Chiaverelli, Rachel ^{[6
]}

Mintah, Eric ^{[6
]}

Nath, Rajneesh ^{[7
]}

Stein, Eytan M. ^{[8
]}

Palmisiano, Neil ^{[9
]}

Sutamtewagul, Grerk ^{[2
]}

Verstovsek, Srdan ^{[10
]}

机构：

[1] Florida Canc Specialists & Res Inst, Sarah Cannon Res Inst, Sarasota, FL USA

[2] Univ Iowa Hosp & Clin, Dept Med, Iowa City, IA 52242 USA

[3] NCI, Norton Healthcare, Louisville, KY USA

[4] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA

[5] Tennessee Oncol, Sarah Cannon Res Inst, Nashville, TN USA

[6] Prelude Therapeut, Res & Dev, Wilmington, DE USA

[7] Univ Texas MD Anderson Canc Ctr, Banner Hlth, Gilbert, AZ USA

[8] Mem Sloan Kettering Canc Ctr, Dept Med, Leukemia Serv, 1275 York Ave, New York, NY 10021 USA

[9] Thomas Jefferson Univ, Dept Med Oncol, Philadelphia, PA 19107 USA

[10] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

来源：

BLOOD | 2021年 / 138卷

关键词：

D O I：

10.1182/blood-2021-150938

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

2609

引用

页数：7

共 50 条

[21] Novel inhibitors of protein arginine methyltransferase 5 (PRMT5) for the treatment of solid tumors
Chikkanna, Dinesh
Panigrahi, Sunil Kumar
Rajagopalan, Sujatha
Sammeta, Srinivasa Raju
Lakshminarasimhan, Anirudha
Mohan, R.
Narasihmarao, K.
Chawla, Darshan
Bhat, Harsha
Kasturi, Venkateswarlu
Samiulla, D. S.
Prasanna, Angelene
Aithal, Kiran
Chand, Priyabrata Chand
Kumar, Naveen
Marri, Sai Sudheer
Ganipisetty, Srinivasa Rao
Rao, Kasieswara N.
Mutyala, Raju
Neerukattu, Nageswara Rao
Nithesh, K.
Amin, Ramya
Gorade, Priyanka Machhindra
Antony, Thomas
Daginakatte, Girish
Chelur, Shekar
Pandit, Chetan
Samajdar, Susanta
Ramachandra, Murali
MOLECULAR CANCER THERAPEUTICS, 2018, 17 (01)
[22] METEOR-1: A phase I study of the safety and efficacy of the protein arginine methyltransferase 5 (PRMT5) inhibitor GSK3326595 in advanced solid tumors
Postel-Vinay, S.
Italiano, A.
Romano, P. Martin
Cassier, P. A.
Siu, L. L.
Lossos, I. S.
Hilton, J. F.
Mckean, M. A.
Strauss, J.
Falchook, G. S.
de Jonge, M. J. A.
Opdam, F. L.
Rasco, D.
Vermaat, J. S.
Crossman, T.
Zajac, M.
Hainline, A.
Kremer, B.
Barbash, O.
Gounder, M. M.
ANNALS OF ONCOLOGY, 2022, 33 (07) : S746 - S747
[23] Protein arginine methyltransferase 5 (PRMT5) is a novel coactivator of constitutive androstane receptor (CAR)
Kanno, Yuichiro
Inajima, Jun
Kato, Sayaka
Matsumoto, Maika
Tokumoto, Chikako
Kure, Yuki
Inouye, Yoshio
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2015, 459 (01) : 143 - 147
[24] Myc and Omomyc functionally associate with the Protein Arginine Methyltransferase 5 (PRMT5) in glioblastoma cells
Mongiardi, Maria Patrizia
Savino, Mauro
Bartoli, Laura
Beji, Sara
Nanni, Simona
Scagnoli, Fiorella
Falchetti, Maria Laura
Favia, Annarita
Farsetti, Antonella
Levi, Andrea
Nasi, Sergio
Illi, Barbara
SCIENTIFIC REPORTS, 2015, 5
[25] Myc and Omomyc functionally associate with the Protein Arginine Methyltransferase 5 (PRMT5) in glioblastoma cells
Maria Patrizia Mongiardi
Mauro Savino
Laura Bartoli
Sara Beji
Simona Nanni
Fiorella Scagnoli
Maria Laura Falchetti
Annarita Favia
Antonella Farsetti
Andrea Levi
Sergio Nasi
Barbara Illi
Scientific Reports, 5
[26] RioK1, a New Interactor of Protein Arginine Methyltransferase 5 (PRMT5), Competes with pICln for Binding and Modulates PRMT5 Complex Composition and Substrate Specificity
Guderian, Gernot
Peter, Christoph
Wiesner, Julia
Sickmann, Albert
Schulze-Osthoff, Klaus
Fischer, Utz
Grimmler, Matthias
JOURNAL OF BIOLOGICAL CHEMISTRY, 2011, 286 (03) : 1976 - 1986
[27] METEOR-1: A phase I study GSK3326595, a first-in-class protein arginine methyltransferase 5 (PRMT5) inhibitor, in advanced solid tumours
Siu, L. L.
Rasco, D. W.
Vinay, S. Postel
Romano, P. Martin
Menis, J.
Opdam, F. L.
Heinhuis, K. M.
Egger, J. L.
Gorman, S. A.
Parasrampuria, R.
Wang, K.
Kremer, B. E.
Gounder, M. M.
ANNALS OF ONCOLOGY, 2019, 30 : 159 - 159
[28] LLY-283, a Potent and Selective Inhibitor of Arginine Methyltransferase 5, PRMT5, with Antitumor Activity
Bonday, Zahid Q.
Cortez, Guillermo S.
Grogan, Michael J.
Antonysamy, Stephen
Weichert, Ken
Bocchinfuso, Wayne P.
Li, Fengling
Kennedy, Steven
Li, Binghui
Mader, Mary M.
Arrowsmith, Cheryl H.
Brown, Peter J.
Eram, Mohammad S.
Szewczyk, Magdalena M.
Barsyte-Lovejoy, Dalia
Vedadi, Masoud
Guccione, Ernesto
Campbell, Robert M.
ACS MEDICINAL CHEMISTRY LETTERS, 2018, 9 (07): : 612 - 617
[29] PRIMAVERA: A Modular Phase I/II Study to Evaluate the Safety, Tolerability, and Efficacy of AZD3470, a Protein Arginine Methyltransferase 5 (PRMT5) Inhibitor, in Participants with Relapsed/Refractory Hematologic Malignancies
Kim, Tae Min
Lewis, Katharine L.
Alderuccio, Juan Pablo
Lee, Hun Ju
Derenzini, Enrico
Zinzani, Pier Luigi
Ladetto, Marco
Ghesquieres, Herve
Phillips, Elizabeth H.
Lemonnier, Francois
Morschhauser, Franck
Balari, Ana Sureda
Izquierdo, Antonia Rodriguez
Borchmann, Peter
Weinstock, Matthew
Svoboda, Jakub
Dean, Emma
Urosevic, Jelena
Meyer, Stefanie
Chen, Robert
Olsson, Richard
Beyfuss, Kaitlyn
Collins, Graham P.
BLOOD, 2024, 144 : 16742 - 16743
[30] Arginine methylation regulates IL-2 gene expression:: a role for protein arginine methyltransferase 5 (PRMT5)
Richard, S
Morel, M
Cléroux, P
BIOCHEMICAL JOURNAL, 2005, 388 : 379 - 386

← 1 2 3 4 5 →